01:24 PM EDT, 05/08/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) shares rose more than 13% in recent Wednesday trading, a day after the company reported a narrower Q1 adjusted loss and higher revenue.

The company reported an adjusted loss late Tuesday of $0.01 per diluted share, narrowing from a loss of $0.21 per share a year earlier. Analysts polled by Capital IQ expected a loss of $0.11.

Revenue for the quarter ended March 31 was $202.2 million, up from $181.2 million a year earlier. Analysts surveyed by Capital IQ expected $193.3 million.

The company said it continues to expect a full-year 2024 adjusted EPS of $0.00 to $0.05. Analysts polled by Capital IQ expect $0.03.

Full-year revenue is expected to be $820 million to $840 million, the company said. Analysts surveyed by Capital IQ expect $830.5 million.

Price: 22.38, Change: +2.60, Percent Change: +13.14